Molecular insights into renal interstitial fibrosis

Journal of the American Society of Nephrology

Volumn 7, Issue 12, 1996, Pages 2495-2508

  Eddy, Allison A ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Metalloproteinases inhibitors; Plasminogen activator inhibitors; Renal fibrosis; Transforming growth factor beta 1; Tubular atrophy

Indexed keywords

ANGIOTENSIN; BASIC FIBROBLAST GROWTH FACTOR; ENDOTHELIN 1; INTERLEUKIN 1; MATRIX PROTEIN; METALLOPROTEINASE; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROTEINASE INHIBITOR; SERINE PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ETIOLOGY; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; HUMAN; KIDNEY DISEASE; KIDNEY INTERSTITIUM; KIDNEY ISCHEMIA; KIDNEY NECROSIS; KIDNEY TUBULE CELL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030419494     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Risdon RA, Sloper JC, de Vardener HE: Relationship between renal function and histologic changes found in renal-biopsy specimens from patients with persistent glomerulonephritis. Lancet 1968;2:363-366.
2. Schainuck LI, Stricker GE, Cutler RE, Benditt EP: Structural-functional correlations in renal disease. Part II. The correlations. Hum Pathol 1970;1:631-641.
3. Kim KH, Kim Y, Gubler MC, et al.: Structural- functioning relationships in Alport syndrome. J Am Soc Nephrol 1995;5:1659-1668.
4. Mackensen-Haen S, Bohie A, Christensen J, Wehrmann M, Kendziorra H, Korot E: The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases. Clin Nephrol 1992;37:70-77.
5. Koch R: Die aetiologie der tuberculose. Berl Klin Wschr 1882:19:221. [Translated by Dr. and Mrs. Max Pinner for the National Tuberculosis Association: The aetiology of tuberculosis. Baltimore; Waverly Press. Inc.: 1932:1-48.
6. Koch R: Die aetiologie der tuberculose. Berl Klin Wschr 1882:19:221. [Translated by Dr. and Mrs. Max Pinner for the National Tuberculosis Association: The aetiology of tuberculosis. Baltimore; Waverly Press. Inc.: 1932:1-48.
7. Gharaee-Kermani M, Wiggins R, Wolber F, Goyal M, Phan SH: Fibronectin is the major fibroblast chemoattractant in rabbit anti-glomerular basement membrane disease. Am J Pathol 1996;148:961-967.
8. Tang WW, Feng L, Xia Y, Peters J, Wilson CB: Expression of embryonic (E) fibronectins (FN) due to alternative splicing after immune renal injury. J Am Soc Nephrol 1993;4:667.
9. Bergijk EC, Kootstra CJ, Baelde HJ, De Heer E, Killen PD, Bruijn JA: Cloning of the mouse fibronectin V- region and variation of its splicing pattern in experimental immunoecomplex glomerulonephritis. J Pathol 1996;178:462-468.
10. Kootstra CJ, Bergijk EC, Veninga A, et al.: Qualitative alterations in laminin expression in experimental lupus nephritis. Am J Pathol 1995;147:476-488.
11. Viedt C, Büuger A, Hänsch GM: Fibronectin synthesis in tubular epithelial cells: Up-regulation of the EDA splice variant by transforming growth factor β. Kidney Int 1995;48:1810-1817.
12. Davies M, Kastner S, Thomas GJ: Proteoglycans: Their possible role in renal fibrosis. Kidney Int 1996;49:S55- S60.
13. Ruoslahti E, Yamaguchi Y: Proteoglycans as modulators of growth factor activities. Cell 1991;64:867-869.
14. Hällgren R, Gerdin B, Tufveson G: Hyaluronic acid accumulation and redistribution in rejecting rat kidney graft. Relationship to the transplantation edema. J Exp Med 1990;171:2063-2076.
15. Hugo C, Pichler R, Meek R, et al.: Thrombospondin 1 is expressed by proliferating mesangial cells and is up- regulated by PDGF and bFGF in vivo. Kidney Int 1995; 48:1846-1856.
16. Hugo C, Pichler R, Shankland S, Couser WG, Johnson RJ: Thrombospondin 1 (TSP1) precedes and predicts tubulo-interstitial fibrosis in glomerular disease [Abstract]. J Am Soc Nephrol 1995;6:897A.
17. Gilbert R, Wu L, Cox A, Roe C, Dziadek M, Cooper ME: TGF-β and SPARC are increased in subtotal nephrectomy [Abstract]. J Am Soc Nephrol 1995;6:1013A.
18. Pichler RH, Hugo C, Reed MJ, et al.: SPARC is expressed in areas of tubulointerstitial and vascular injury in experimental models of renal disease [Abstract]. J Am Soc Nephrol 1995;6:907A.
19. Nakao N, Yoshiki A, Hiraiwa N, Kusakabe M: Tenascin is an important matrix protein during the healing process of murine mesangial proliferative glomerulone- phritis. J Am Soc Nephrol 1995;6:903.
20. Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA: Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. Kidney Int 1991;40: 1020-1031.
21. Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA: Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 1992;141:1381-1396.
22. Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M: TGF-β1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int 1994;45:525-536.
23. Lee R, Wiggins R, Goyal M, Dysko R, Killen PD: Renal biopsy collagen I (CI) mRNA predicts renal scarring in a model of crescentic nephritis in rabbits [Abstract]. J Am Soc Nephrol 1995;6:903A.
24. Sharma AK, Mauer SM, Kim Y, Michael AF: Interstitial fibrosis in obstructive nephropathy. Kidney Int 1993; 44:774-788.
25. Rodemann HP, Müller GA, Knecht A, Norman JT, Fine LG: Fibroblasts of rabbit kidney in culture. I. Characterization and identification of cell-specific markers. Am J Physiol 1991;261:F283-F291.
26. Kovacs EJ, DiPietro LA: Fibrogenic cytokines and connective tissue production. FASEB J 1994;8:854-861.
27. Korfhagen TR, Swantz RJ, Wert SE, et al.: Respiratory epithelial cell expression of human transforming growth factor-α induces lunch fibrosis in transgenic mice. J Clin Invest 1994;93:1691-1699.
28. De Petro G, Copeta A, Barlati S: Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts. Experiment Cell Res 1994;213: 286-294.
29. Gray AJ, Park PW, Broekelmann TJ, et al.: The mitogenic effects of the B beta chain of fibrinogen are mediated through cell surface calreticulin. J Biol Chem 1995;270:26602-26606.
30. Fujisaki H, Ito H, Hirata Y, et al.: Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995;96:1059-1065.
31. Lonnemann G, Shapiro L, Engler-Blum G, Muller GA, Koch KM, Dinarello CA: Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int 1995;47:837-844.
32. Alvarez RJ, Sun MJ, Haverty TP, Iozzo RV, Myers JC, Neilson ECG: Biosynthetic and proliferative characteristics of tubulointerstitial fibroblasts probed with paracrine cytokines. Kidney Int 1992;41:14-23.
33. Müller GA, Rodemann HP: Characterization of human renal fibroblasts in health and disease. I. Immunophenotyping of cultured tubular epithelial cells and fibroblasts derived from kidneys and histologically proven interstitial fibrosis. Am J Kidney Dis 1991;17:680-683.
34. Rodemann HP, Müller GA: Characterization of human renal fibroblasts in health and disease. II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney Dis 1991;17:684-686.
35. Alpers CE, Hudkins KL, Floege J, Johnson RJ: Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. J Am Soc Nephrol 1994;5:201-210.
36. Goumenos DS, Brown CB, Shortland J, el Nahas AM: Myofibroblasts, predictors of progression of mesangial IgA nephropathy? Nephrol Dial Tansplant 1994;9: 1418-1425.
37. Kliem V, Johnson RJ, Alpers CE, et al.: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 1996;49: 666-678.
38. Johnson RJ, Alpers CE, Yoshimura A, et al: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464-474.
39. Eng E, Veniant M, Floege J, et al.: Renal proliferative and phenotypic changes in rats with two-kidney, one- clip Goldblatt hypertension. Am J Hypertension 1994; 7:177-185.
40. Diamond JR, van Goor H, Ding G, Engelmyer E: Myofibroblasts in experimental hydronephrosis. Am J Pathol 1995;146:121-129.
41. Zhang G, Moorhead PJ, el Nahas AM: Myofibroblasts and the progression of experimental glomerulonephritis. Exp Nephrol 1995;3:308-318.
42. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G: Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103-111.
43. Tang WW, Ulich TR, Lacey DL, et al.: Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol 1996;148:1169-1180.
44. Wiggins R, Goyal M, Merritt S, Killen PD: Vascular adventitial cell expression of collagen I messenger ribonucleic acid in anti-glomerular basement membrane antibody-induced crescentic nephritis in the rabbit. A cellular source for interstitial collagen synthesis in inflammatory renal disease. Lab Invest 1993;68:557-565.
45. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ: The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995; 95:859-873.
46. Vaage J, Lindblad WJ: Production of collagen type I by mouse peritoneal macrophages. J Leukoc Biol 1990;48: 274-280.
47. Hooke DH, Gee DC, Atkins RC: Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int 1987;31:964-972.
48. Cameron JS: Tubular and interstitial factors in the progression of glomerulonephritis. Pediatr Nephrol 1992;6:292-303.
49. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC: Local macrophage proliferation in multinucleated giant cell and granuloma formation in experimental Goodpasture's syndrome. Am J Pathol 1995;147:1214-1220.
50. Lan HY, Nikokic-Paterson DJ, Mu W, Atkins RC: Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int 1995;48:753-760.
51. Ceol M, Nerlich A, Baggio B, et al.: Increased glomerular α1(IV) collagen expression and deposition in long- term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest 1996;74:484-495.
52. Creely JJ, DiMari SJ, Howe AM, Haralson MA: Effects of transforming growth factor-β on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol 1992;140:45-55.
53. Nadasdy T, Laszik Z, Blick KE, Johnson DL, Silva FG: Tubular atrophy in the end-stage kidney: A lectin and immunohistochemical study. Hum Pathol 1994;25:22-28.
54. Strutz F, Okada H, Lo CW, et al: Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995;130:393-405.
55. Gonzáalez-Avila G, Vadillo-Ortega F, Pérez-Tamayo R: Experimental diffuse interstitial renal fibrosis. A biochemical approach. Lab Invest 1988;59:245-252.
56. Walker PD: Alterations in renal tubular extracellular matrix components after ischemia-reperfusion injury to the kidney. Lab Invest 1994;70:339-346.
57. Stetler-Stevenson WG: Dynamics of matrix turnover during pathologic Oremodeling of the extracellular matrix. Am J Pathol 1996;148:1345-1350.
58. Birkedal-Hansen H, Moore WGI, Bodden MK, et al.: Matrix metalloproteinases: A review. Clin Rev Oral Biol Med 1993;4:197-250.
59. Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47: 1546-1557.
60. Eddy AA: Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int 1996;50:1139-1149.
61. Eddy A, Li Z, Liu E, McCulloch L: Macrophages may mediate interstitial fibrosis via the release of transforming growth factor β1 in passive Heymann nephritis [Abstract]. J Am Soc Nephrol 1991;2:573A.
62. Eddy A: Protein restriction reduces transforming growth factor-β and interstitial fibrosis in nephrotic syndrome. Am J Physiol 1994;35:F884-F893.
63. Sharma AK, Mauer SM, Kim Y, Michael AF: Altered expression of matrix metalloproteinase-2, TIMP, and TIMP-2 in obstructive nephropathy. J Lab Clin Med 1995;125:754-761.
64. Engelmyer E, van Goor H, Edwards DR, Diamond JR: Differential mRNA expression of renal cortical tissue inhibitor of metalloproteinase-1, -2, and -3 in experimental hydronephrosis. J Am Soc Nephrol 1995;5: 1675-1683.
65. Wu K, Setty S, Staskus K, Mauer M, Rozen S, Tsilibary EC: Altered matrix gene expression in experimental diabetes [Abstract]. J Am Soc Nephrol 1995;6:915A.
66. Eddy AA: Expression of genes that promote renal interstitial fibrosis in rats with proteinuria. Kidney Int 1996; 49:S49-S54.
67. Norman JT, Gatti L, Wilson PD, Lewis M: Matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases expression by tubular epithelia and interstitial fibroblasts in the normal kidney and in fibrosis. Exper Nephrol 1995;3:88-89.
68. Schaefer L, Han X, Gretz N, et al.: Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han:SPRD rat. Kidney Int 1996;49:75-81.
69. Norman JT, Lewis MP: Matrix metalloproteinases (MMPs) in renal fibrosis. Kidney Int 1996;49:S61-S63.
70. Lewis MP, Fine LG, Norman JT: Pexicrine effects of basement membrane components on paracrine signaling by renal tubular cells. Kidney Int 1996;49:48-58.
71. Vassalli J-D, Sappino A-P, Belin D: The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-1072.
72. Tomooka S, Border WA, Marshall BC, Noble NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992;42: 1462-1469.
73. Lyons RM, Keski-Oja J, Moses HL: Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol 1988;106: 1659-1665.
74. Eitzman DT, McCoy RD, Zheng X, et al.: Bleomycin- induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97:232-237.
75. Kovacs EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 1991;12:17-23.
76. Border WA, Noble NA: Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
77. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994;266:F829-F842.
78. Pichler RH, Franceschini N, Young BA, et al.: Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995;6:1186-1196.
79. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916-927.
80. Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo NC: Macrophages, monocyte chemoattractant peptide-1, and TGF-β1 in experimental hydronephrosis. Am J Physiol 1994;226:F926-F933.
81. Wright EJ, McCaffrey TA, Robertson AP, Vaughan Jr ED, Felsen D: Chronic unilateral ureteral obstruction is associated with interstitial fibrosis and tubular expression of transforming growth factor-β. Lab Invest 1996; 74:528-537.
82. Basile DP, Rovak JM, Martin DR, Hammerman MR: Increased transforming growth factor-β1 expression in regenerating rat renal tubules following ischemic injury. Am J Physiol 1996;270:F500-F509.
83. Yamamoto T, Noble NA, Cohen AH, et al.: Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int 1996;49:461-469.
84. Shihab FS, Yamamoto T, Nast CC, et al.: Transforming growth factor-β and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 1995;6:286-294.
85. Sharma VK, Bologa RM, Xu G-P, et al.: Intragraft TGF-β1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996;49: 1297-1303.
86. Gaciong Z, Koziak K, Religa P, et al.: Increased expression of growth factors during chronic rejection of human kidney allograft. Transplant Proc 1995;27:928-929.
87. Miyazono K, Ichijo H, Heldin C-H: Transforming growth factor-β: Latent forms, binding proteins and receptors. Growth Factors 1993;8:11-22.
88. Jullien P, Berg TM, Lawrence DA: Acidic cellular environments: Activation of latent TGF-β and sensitization of cellular responses to TGF-β and EGF. Int J Cancer 1989;43:886-891.
89. Dubois CM, Laprise M-H, Blanchette F, Gentry LE, Leduc R: Processing of transforming growth factor β1 precursor by human furin convertase. J Biol Chem 1995;10618-10624.
90. Miyazono K, Heldin CH: Role for carbohydrate structures in TGF-beta 1 latency. Nature (Lond) 1989;338: 158-160.
91. Schultz-Cherry S, Lawler J, Murphy-Ullrich JE: The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem 1994; 269:26783-26788.
92. Ando T, Okuda S, Tamaki K, Yoshitomi K, Fujishima M: Localization of transforming growth factor-β and latent transforming growth factor-β binding protein in rat kidney. Kidney Int 1995;47:733-739.
93. Tamaki K, Okuda S, Miyazono K, Nakayama M, Fujishima M: Matrix-associated latent TGF-β with latent TGF-β binding protein in the progressive process in adriamycin-induced nephropathy. Lab Invest 1995;73: 81-89.
94. Feige J-J, Baird A: Crinopexy: Extracellular regulation of growth factor action. Kidney Int 1995;47[Suppl 49]: S15-S18.
95. van Goor H, Joles JA, van der Horst MLC, Koomans HA, Kaysen GA: α2-Macroglobulin (α2 M) and transforming growth factor (TGF)-β in nephrotic rats [Abstract]. J Am Soc Nephrol 1995;6:1033A.
96. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature (Lond) 1990;346:371-374.
97. Border WA, Noble NA, Yamamoto T, et al.: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature (Lond) 1992;360:361-364.
98. Isaka Y, Brees DK, Ikegaya K, et al.: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 1996;2:418-423.
99. Boivin GP, O'Toole BA, Orsmby IE, et al.: Onset and progression of pathological lesions in transforming growth factor-β1-deficient mice. Am J Pathol 1995;146: 276-288.
100. Kulkarni AB, Ward JM, Yaswen L, et al.: Transforming growth factor-β1 null mice. An animal model for inflammatory disorders. Am J Pathol 1995;146:264-275.
101. Sanderson N, Factor V, Nagy P, et al.: Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995;92:2572-2576.
102. Kopp JB, Factor VM, Mozes M, et al.: Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest 1996;74:991-1003.
103. Terrell TG, Working PK, Chow CP, Green JD: Pathology of recombinant human transforming growth factor-β1 in rats and rabbits. Int Rev Exp Pathol 1993; 34B:43-67.
104. Yoshioka K, Takemura T, Murakami K, et al.: In situ expression of cytokines in IgA nephritis. Kidney Int 1993;44:825-833.
105. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 1996;49:578-597.
106. Wolf G, Mueller E, Stahl RAK, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 1993;92:1366-1372.
107. Ruiz-Ortega M, González E, Egido J: Molecular characterization of angiotensin II effects on renal interstitial fibroblasts [Abstrac[]. J Am Soc Nephrol 1995;6:909A.
108. Pimentel JL Jr, Sundell CL, Wang S, Kopp JB, Montero A, Martínez-Maldonado M: Role of angiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy. Kidney Int 1995;48:1233-1246.
109. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S: Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int 1994;45:1637-1647.
110. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995;47:1285-1294.
111. Burdmann EA, Andoh TF, Nast CC, et al.: Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995;269: F491-F499.
112. Diamond JR, Anderson S: Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 1990;137:1323-1332.
113. Norman JT, Gallego C, Bridgeman DA: Enalapril ameliorates interstitial fibrosis in the remnant kidney of the rat. J Am Soc Nephrol 1992;3:746.
114. Inserra F, Romano LA, de Cavanagh EMV, Ercole L, Ferder LF, Gomez RA: Renal interstitial sclerosis in again: Effects of enalapril and nifedipine. J Am Soc Nephrol 1996;7:676-680.
115. Ruiz-Ortega M, Gonzalez S, Serón D, et al.: ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995; 48:1778-1791.
116. Ghiggeri GM, Valenti F, Oleggini R, et al.: Stimulation by angiotensin II of αI(III) collagen transcription in renal cells [Abstract]. J Am Soc Nephrol 1995;6:895A.
117. Niimura F, Labosky PA, Kakuchi J, et al.: Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995; 96:2947-2954.
118. Nath KA: Reshaping the interstitium by platelet- derived growth factor. Am J Pathol 1996;148:1031-1036.
119. Fellström B, Klareskog L, Heldin CH, et al.: Platelet- derived growth factor receptors in the kidney - Upregulated expression in inflamation. Kidney Int 1989;36:1099-1102.
120. Gesualdo L, Di Paolo S, Milani S, et al.: Expression of platelet-derived growth factor receptors in normal and diseased human kidney. J Clin Invest 1994;94:50-58.
121. Nikolic-Paterson DJ, Main IW, Tesch GH, Lan HY, Atkins RC: Interleukin-1 in renal fibrosis. Kidney Int 1996;49:S88-S90.
122. Lan HY, Nikolic-Paterson DJ, Zarama M, Vannice JL, Atkins RC: Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int 1993;43:479-485.
123. Lan HY, Nikolic-Paterson J, Mu W, Vannice JL, Atkins RC: Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int 1995;47:1303-1309.
124. Morita H, Shinzato T, David G, et al.: Basic fibroblast growth factor-binding domain of heparan sulfate in the human glomerulosclerosis and renal tubulointerstitial fibrosis. Lab Invest 1994;71:528-535.
125. Ichimura T, Maier JA-M, Maciag T, Zhang G, Stevens JL: FGF-1 in normal and regenerating kidney: expression in mononuclear, interstitial, and regenerating epithelial cells. Am J Physiol 1995;269:F653-F662.
126. Ray PE, Bruggeman LA, Weeks BS, et al.: bFGF and its low affinity receptors in the pathogenesis of HIV- associated nephropathy in transgenic mice. Kidney Int 1994;46:759-772.
127. Fine LG, Norman JT, Ong A: Cell-cell cross-talk in the pathogenesis of renal interstitial fibrosis. Kidney Int 1995;47:348-550.
128. Kawaguchi Y, Suzuki K, Hara M, et al.: Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994; 53:506-510.
129. Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond) 1988;332:411-415.
130. Ehrenreich H, Anderson RW, Fox CH, et al.: Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990; 172:1741-1748.
131. Ong ACM, Jowett TP, Firth JD, Burton S, Kitamura M, Fine LG: Human tubular-derived endothelin in the paracrine regulation of renal interstitial fibroblast function [Abstract]. Exp Nephrol 1994;2:134A.
132. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT: Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993;27:2130-2134.
133. Nakamura T, Ebihara I, Fakui M, et al.: Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Renal Physiol Biochem 1993;16:233-243.
134. Benigni A, Zoja C, Corna D, et al.: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440- 444.
135. Nakamura T, Ebihara I, Tomino Y, Koide H: Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995;47:481-489.
136. Zoja C, Morigi M, Figliuzzi M, et al.: Proximal tubular cell synthesis and secretion of endothelin-1 on challenge and albumin and other proteins. Am J Kidney Dis 1995;26:934-941.
137. Marcussen N: Biology of disease. Atubular glomeruli and the structural basis for chronic renal failure. Lab Invest 1992;66:265-284.
138. Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994;5:1273-1287.
139. Ong ACM, Fine LG: Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis: Implications for human renal disease progression. Am J Kidney Dis 1994;23:205-209.
140. Truong LD, Petrusevska G, Yang G, et al.: Cell apoptosis and proliferation in experimental chronic obstructive uropathy. Kidney Int 1996;50:200-207.
141. Ljungquist A: The intrarenal arterial pattern in the normal and diseases human kidney. Acta Med Scand 1963;174:5-34.
142. Bohle A, Gise HV, Mackensen-Haen S, Start-Jacob B: The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli. Klin Wochenschr 1981;59:1043-1051.
143. Serón D, Alexopoulos E, Raftery MJ, Hartley B, Cameron JS: Number of interstitial capillary cross-sections assessed by monoclonal antibodies: Relation to interstitial damage. Nephrol Dial Transplant 1990;5: 889-893.
144. Ong ACM, Fine LG: Loss of glomerular function and tubulointerstitial fibrosis: Cause or effect? Kidney Int 1994;45:345-351.
145. Truong LD, Farhood A, Tasby J, Gillum D: Experimental chronic renal ischemia: Morphologic and immunologic studies. Kidney Int 1992;41:1676-1689.
146. Orphanides C, Norman J: Hypoxia modulates expression of matrix metallo-proteinases (MMPs) and tissue inhibitors of metallo-proteinases (TIMP-1): A role in fibrosis? J Am Soc Nephrol 1995;6:906.
147. Albina JE, Henry WL Jr, Mastrofrancesco B, Martin B-A, Reichner JS: Macrophage activation by culture in an anoxic environment. J Immunol 1995;155:4391-4396.
148. Coimbra T, Wiggins R, Noh JW, Merritt S, Phan SH: Transforming growth factor-β production in anti- glomerular basement membrane disease in the rabbit. Am J Pathol 1991;138:223-234.
149. Nakamura T, Ebihara I, Nagaoka I, Osada S, Tomino Y, Koide H: Effect of methylprednisolone on transforming frowth factor-beta, insulin-like growth factor-I, and asic fibroblast growth factor gene expression in the kidneys of NZB/W F1 mice. Renal Physiol Biochem 1993;16:105-116.
150. Bodi I, Kimmel PL, Abraham AA, Sporn MB, Klotman PE, Kopp JB: Increased TGF-β expression in human HIV-associated nephropathy [Abstract]. J Am Soc Nephrol 1993;4:461A.
151. Border W, Yamamoto T, Noble N, Gold L, Nast C, Cohen A: HIV-associated nephropathy is linked to TGF-β and matrix protein expression in human kidney [Abstract]. J Am Soc Nephrol 1993;4:675A.
152. Shankland SJ, Scholey JW: Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Clin Invest 1994;46:430-442.
153. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
154. Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993;44:313-321.
155. Nakamura T, Ebihara I, Nagaoka I, et al.: Growth factor gene expression in kidney of murine polycystic kidney disease. J Am Sor Nephrol 1993;3:1378-1386.
156. Shihab FS, Andoh TF, Tanner AM, et al.: Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996;49:1141-1151.
157. Goes N, Urmson J, Ramassar V, Halloran PF: Ischemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon- gamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995;59:565-572.
158. Niemir ZI, Stein H, Noronha IL, et al.: PDGF and TGF-β contribute to the natural course of human IgA glomerulonephritis. Kidney Int 1995;48:1530-1541.
159. Schena FP, Gesualdo L, Ranieri E, Montinaro V: Prospective study on cytokine renal expression in human proliferative glomerulonephritis (GN). Search for pathogenetic factors and prognostic indicators [Abstract]. Blood Purif 1996;14:81A.